Visual Abstract

Clinical outcomes describing real-world use of various devices by people with T1D are important to support decision-making. This retrospective study characterized patient-reported clinical outcomes in youth in the United States with T1D before (baseline) and 90 days after (follow-up) the initiation of a tubeless insulin pump (Omnipod® or Omnipod DASH® Insulin Management System). The primary outcome was change in self-reported HbA1c from baseline to follow-up. Secondary outcomes were change in self-reported total daily dose (TDD) of insulin and frequency of hypoglycemic events (HE) per week (#/week <70 mg/dL). Outcomes were assessed overall and stratified by prior treatment modality (MDI or CSII) and age group. Patients were aged 11.2±3.8y (mean ± SD). The overall change in self-reported HbA1c at follow-up was -0.5±1.6% (p<0.0001). Overall change in TDD of insulin was -1.2±12.3U/d and the self-reported HE frequency decreased significantly by -1.4±2.9 episodes per week (p<0.0001). Reductions in HbA1c, TDD and HE were seen regardless of prior treatment or age group (except for patients <6y who had a slight increase in TDD). In this large cohort of youth with T1D, initiation of a tubeless insulin pump was associated with significant reductions in HbA1c and number of HE after 90 days of use compared to prior MDI and CSII treatments and across age groups.

Disclosure

D. Desalvo: Consultant; Self; Insulet Corporation, Research Support; Self; Insulet Corporation, Speaker’s Bureau; Self; Dexcom, Inc. G. Aleppo: Consultant; Self; Dexcom, Inc., Insulet Corporation, Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk. F. Lauand: Employee; Self; Insulet Corporation. L. M. Huyett: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. J. Jantz: Employee; Self; Insulet Corporation. A. Chang: Employee; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. T. Ly: Employee; Self; Insulet Corporation.

Funding

Insulet Corporation

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.